Related Experiment Video
Updated: May 5, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Case Report: Upadacitinib treatment for Behçet's syndrome with intestinal damage
Ling Yuan1, Yingying Sun1, Jianjun Yan1
1Department of Dermatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
None:
We report the case of a 17-year-old male presenting with recurrent, debilitating oral and genital ulcerations. Diagnostic evaluation confirmed multisystemic Behçet's syndrome with multifocal intestinal involvement. Following the exclusion of infectious contraindications, the patient was initiated on upadacitinib (15 mg daily) as a primary systemic intervention. Remarkable clinical remission of mucocutaneous and gastrointestinal ulcerations was achieved within 1 month. Sustained improvement was observed during subsequent follow-up, suggesting that upadacitinib may serve as an effective therapy for multisystemic Behçet's syndrome in adolescent patients.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
